Human synthetic lethal inference as potential anti-cancer target gene detection

BMC Systems Biology

Volumn 3, Issue , 2009, Pages

  Conde Pueyo, Nuria ^a   Munteanu, Andreea ^a   Solé, Ricard V ^a,b   Rodríguez Caso, Carlos ^a  

^a Barcelona Biomedical Research Park   (Spain)

^b SANTA FE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BIOLOGY; DRUG DESIGN; GENETIC DATABASE; GENETICS; HUMAN; LETHAL GENE; MUTATION; NEOPLASM; PHYLOGENY; SACCHAROMYCES CEREVISIAE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DESIGN; GENES, LETHAL; GENES, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; PHYLOGENY; SACCHAROMYCES CEREVISIAE;

EID: 74549130411     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-3-116     Document Type: Article

References (78)

1. Pereira DA, Williams JA. Origin and evolution of high throughput screening. Br J Pharmacol 2007, 152:53-61. 10.1038/sj.bjp.0707373, 1978279, 17603542.
2. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 2002, 1(11):882-894. 10.1038/nrd941, 12415248.
3. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007, 152:38-52. 10.1038/sj.bjp.0707307, 1978269, 17533416.
4. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness-the Achilles heel of drug-target networks. Nat Biotechnol 2008, 26(9):983-984. 10.1038/nbt0908-983, 18779805.
5. Agarwal P, Searls DB. Literature mining in support of drug discovery. Brief Bioinform 2008, 9(6):479-92. 10.1093/bib/bbn035, 18820304.
6. Weinberg R. The biology of Cancer 2007, Garland. New York.
7. Loeb LA. A mutator phenotype in cancer. Cancer Res 2001, 61(8):3230-3239.
8. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008, 68(10):3551-7. discussion 3557., 10.1158/0008-5472.CAN-07-5835, 18483233.
9. Solé RV, Deisboeck TS. An error catastrophe in cancer?. J Theor Biol 2004, 228:47-54. 10.1016/j.jtbi.2003.08.018, 15064082.
10. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6(12):924-935. 10.1038/nrc2013, 17109012.
11. Fernández A, Crespo A, Tiwari A. Is there a case for selectively promiscuous anticancer drugs?. Drug Discov Today 2009, 14(1-2):1-5. 10.1016/j.drudis.2008.10.008, 19038361.
12. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278(5340):1064-1068. 10.1126/science.278.5340.1064, 9353181.
13. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White MA. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446(7137):815-819. 10.1038/nature05697, 17429401.
14. Meur NL, Gentleman R. Modeling synthetic lethality. Genome Biol 2008, 9(9):R135. 10.1186/gb-2008-9-9-r135, 2592713, 18789146.
15. Wilkie AOM. The molecular basis of genetic dominance. J Med Genet 1994, 31:89-98. 10.1136/jmg.31.2.89, 1049666, 8182727.
16. Davierwala AP, Haynes J, Li Z, Brost RL, Robinson MD, Yu L, Mnaimneh S, Ding H, Zhu H, Chen Y, Cheng X, Brown GW, Boone C, Andrews BJ, Hughes TR. The synthetic genetic interaction spectrum of essential genes. Nat Genet 2005, 37(10):1147-1152. 10.1038/ng1640, 16155567.
17. Kamb A. Mutation load, functional overlap, and synthetic lethality in the evolution and treatment of cancer. J Theor Biol 2003, 223(2):205-213. 10.1016/S0022-5193(03)00087-0, 12814603.
18. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5(9):689-698. 10.1038/nrc1691, 16110319.
19. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3(8):673-683. 10.1038/nrd1468, 15286734.
20. Forsburg SL. The art and design of genetic screens: yeast. Nat Rev Genet 2001, 2(9):659-668. 10.1038/35088500, 11533715.
21. Pan X, Yuan DS, Xiang D, Wang X, Sookhai-Mahadeo S, Bader JS, Hieter P, Spencer F, Boeke JD. A robust toolkit for functional profiling of the yeast genome. Mol Cell 2004, 16(3):487-496. 10.1016/j.molcel.2004.09.035, 15525520.
22. Ooi SL, Pan X, Peyser BD, Ye P, Meluh PB, Yuan DS, Irizarry RA, Bader JS, Spencer FA, Boeke JD. Global synthetic-lethality analysis and yeast functional profiling. Trends Genet 2006, 22:56-63. 10.1016/j.tig.2005.11.003, 16309778.
23. Boone C, Bussey H, Andrews BJ. Exploring genetic interactions and networks with yeast. Nat Rev Genet 2007, 8(6):437-449. 10.1038/nrg2085, 17510664.
24. Jorgensen EM, Mango SE. The art and design of genetic screens: caenorhabditis elegans. Nat Rev Genet 2002, 3(5):356-369. 10.1038/nrg794, 11988761.
25. Baugh LR, Wen JC, Hill AA, Slonim DK, Brown EL, Hunter CP. Synthetic lethal analysis of Caenorhabditis elegans posterior embryonic patterning genes identifies conserved genetic interactions. Genome Biol 2005, 6(5):R45. 10.1186/gb-2005-6-5-r45, 1175957, 15892873.
26. Lehner B, Crombie C, Tischler J, Fortunato A, Fraser AG. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nat Genet 2006, 38(8):896-903. 10.1038/ng1844, 16845399.
27. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Pagé N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H, Andrews B, Tyers M, Boone C. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 2001, 294(5550):2364-2368. 10.1126/science.1065810, 11743205.
28. Tong AHY, Lesage G, Bader GD, Ding H, Xu H, Xin X, Young J, Berriz GF, Brost RL, Chang M, Chen Y, Cheng X, Chua G, Friesen H, Goldberg DS, Haynes J, Humphries C, He G, Hussein S, Ke L, Krogan N, Li Z, Levinson JN, Lu H, Ménard P, Munyana C, Parsons AB, Ryan O, Tonikian R, Roberts T, Sdicu AM, Shapiro J, Sheikh B, Suter B, Wong SL, Zhang LV, Zhu H, Burd CG, Munro S, Sander C, Rine J, Greenblatt J, Peter M, Bretscher A, Bell G, Roth FP, Brown GW, Andrews B, Bussey H, Boone C. Global mapping of the yeast genetic interaction network. Science 2004, 303(5659):808-813. 10.1126/science.1091317, 14764870.
29. Yuen KWY, Warren CD, Chen O, Kwok T, Hieter P, Spencer FA. Systematic genome instability screens in yeast and their potential relevance to cancer. Proc Natl Acad Sci USA 2007, 104(10):3925-3930. 10.1073/pnas.0610642104, 1820685, 17360454.
30. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci USA 2007, 104(21):8685-8690. 10.1073/pnas.0701361104, 1885563, 17502601.
31. Platzer A, Perco P, Lukas A, Mayer B. Characterization of protein-interaction networks in tumors. BMC Bioinformatics 2007, 8:224. 10.1186/1471-2105-8-224, 1929125, 17597514.
32. Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nat Biotechnol 2007, 25(10):1119-1126. 10.1038/nbt1338, 17921997.
33. Chipman K, Singh A. Predicting genetic interactions with random walks on biological networks. BMC Bioinformatics 2009, 10:17. 10.1186/1471-2105-10-17, 2653491, 19138426.
34. Paladugu SR, Zhao S, Ray A, Raval A. Mining protein networks for synthetic genetic interactions. BMC Bioinformatics 2008, 9:426. 10.1186/1471-2105-9-426, 2577120, 18844977.
35. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006, (34 Database):D535-D539. 10.1093/nar/gkj109, 1347471, 16381927.
36. Sonnhammer ELL, Koonin EV. Orthology, paralogy and proposed classification for paralog subtypes. Trends Genet 2002, 18(12):619-620. 10.1016/S0168-9525(02)02793-2, 12446146.
37. Pan X, Ye P, Yuan DS, Wang X, Bader JS, Boeke JD. A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell 2006, 124(5):1069-1081. 10.1016/j.cell.2005.12.036, 16487579.
38. Krogan NJ, Keogh MC, Datta N, Sawa C, Ryan OW, Ding H, Haw RA, Pootoolal J, Tong A, Canadien V, Richards DP, Wu X, Emili A, Hughes TR, Buratowski S, Greenblatt JF. A Snf2 family ATPase complex required for recruitment of the histone H2A variant Htz1. Mol Cell 2003, 12(6):1565-1576. 10.1016/S1097-2765(03)00497-0, 14690608.
39. Maere S, Heymans K, Kuiper M. Bingo: a cytoscape plugging to assess over-representation of gene ontology categories in biological networks. Bioinformatics 2005, 21(16):3448-3449. 10.1093/bioinformatics/bti551, 15972284.
40. The Gene Ontology Consortium Gene Ontology: tool for the unification of biology. Nature Genetics 2000, 25:25-29. 10.1038/75556, 10802651, The Gene Ontology Consortium.
41. Hopkins AL. Network pharmacology. Nat Biotechnol 2007, 25(10):1110-1111. 10.1038/nbt1007-1110, 17921993.
42. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008, (36 Database):D901-D906. 2238889, 18048412.
43. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13(11):2498-2504. 10.1101/gr.1239303, 403769, 14597658.
44. Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, Koonin EV, Krylov DM, Mazumder R, Mekhedov SL, Nikolskaya AN, Rao BS, Smirnov S, Sverdlov AV, Vasudevan S, Wolf YI, Yin JJ, Natale DA. The COG database: an updated version includes eukaryotes. BMC Bioinformatics 2003, 4:41. 10.1186/1471-2105-4-41, 222959, 12969510.
45. Trowbridge K, McKim K, Brill SJ, Sekelsky J. Synthetic lethality of Drosophila in the absence of the MUS81 endonuclease and the DmBlm helicase is associated with elevated apoptosis. Genetics 2007, 176(4):1993-2001. 10.1534/genetics.106.070060, 1950608, 17603121.
46. Zhang R, Sengupta S, Yang Q, Linke SP, Yanaihara N, Bradsher J, Blais V, McGowan CH, Harris CC. BLM helicase facilitates Mus81 endonuclease activity in human cells. Cancer Res 2005, 65(7):2526-2531. 10.1158/0008-5472.CAN-04-2421, 15805243.
47. McManus KJ, Barrett IJ, Nouhi Y, Hieter P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci USA 2009, 106(9):3276-3281. 10.1073/pnas.0813414106, 2651317, 19218431.
48. Kennedy RD, Chen CC, Stuckert P, Archila EM, la Vega MAD, Moreau LA, Shimamura A, D'Andrea AD. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117(5):1440-1449. 10.1172/JCI31245, 1847538, 17431503.
49. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003, 40(9):657-663. 10.1136/jmg.40.9.657, 1735580, 12960210.
50. Lin L, Zhang JH, Panicker LM, Simonds WF. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci USA 2008, 105(45):17420-17425. 10.1073/pnas.0710725105, 2582266, 18987311.
51. Jeronimo C, Forget D, Bouchard A, Li Q, Chua G, Poitras C, Thérien C, Bergeron D, Bourassa S, Greenblatt J, Chabot B, Poirier GG, Hughes TR, Blanchette M, Price DH, Coulombe B. Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Mol Cell 2007, 27(2):262-274. 10.1016/j.molcel.2007.06.027, 17643375.
52. Labhart P, Morgan GT. Identification of novel genes encoding transcription elongation factor TFIIS (TCEA) in vertebrates: conservation of three distinct TFIIS isoforms in frog, mouse, and human. Genomics 1998, 52(3):278-288. 10.1006/geno.1998.5449, 9790746.
53. Knudsen KA, Wheelock MJ. Plakoglobin, or an 83-kD homologue distinct from beta-catenin, interacts with E-cadherin and N-cadherin. J Cell Biol 1992, 118(3):671-679. 10.1083/jcb.118.3.671, 2289540, 1639850.
54. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, Fearon ER. Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000, 14(11):1319-1331. 316666, 10837025.
55. Massagué J. G1 cell-cycle control and cancer. Nature 2004, 432(7015):298-306. 10.1038/nature03094, 15549091.
56. Tarailo M, Kitagawa R, Rose AM. Suppressors of spindle checkpoint defect (such) mutants identify new mdf-1/MAD1 interactors in Caenorhabditis elegans. Genetics 2007, 175(4):1665-1679. 10.1534/genetics.106.067918, 1855113, 17237515.
57. Litman R, Gupta R, Brosh RM, Cantor SB. BRCA-FA pathway as a target for anti-tumor drugs. Anticancer Agents Med Chem 2008, 8(4):426-430. 2564853, 18473727.
58. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007, 4(2):59-71. 1796947, 17299578.
59. Chen J, Larochelle S, Li X, Suter B. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature 2003, 424(6945):228-232. 10.1038/nature01746, 12853965.
60. Lolli G, Johnson LN. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?. Cell Cycle 2005, 4(4):572-577.
61. Stefansson B, Brautigan DL. Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle 2007, 6(11):1386-1392.
62. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994, 91(2):709-713. 10.1073/pnas.91.2.709, 43018, 8290586.
63. Sanchez G, Delattre O, Auboeuf D, Dutertre M. Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity. Cell Cycle 2008, 7(15):2299-2305.
64. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392(6673):300-303. 10.1038/32688, 9521327.
65. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998, 18(4):259-296. 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.0.CO;2-U, 9664292.
66. Schäfer M, Werner S. Oxidative stress in normal and impaired wound repair. Pharmacol Res 2008, 58(2):165-171. 10.1016/j.phrs.2008.06.004, 18617006.
67. Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, Park HS, Kim KY, Lee JS, Choi C, Bae YS, Lee BI, Rhee SG, Kang SW. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 2005, 435(7040):347-353. 10.1038/nature03587, 15902258.
68. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol 2007, 85(4):509-520. 10.1139/O07-069, 17713585.
69. Sinha S, Yang W. Cellular signaling for activation of Rho GTPase Cdc42. Cell Signal 2008, 20(11):1927-1934. 10.1016/j.cellsig.2008.05.002, 18558478.
70. Pulgar TGD, Valdés-Mora F, Bandrés E, Pérez-Palacios R, Espina C, Cejas P, García-Cabezas MA, Nistal M, Casado E, González-Barón M, García-Foncillas J, Lacal JC. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol 2008, 33:185-193.
71. Pelish HE, Peterson JR, Salvarezza SB, Rodriguez-Boulan E, Chen JL, Stamnes M, Macia E, Feng Y, Shair MD, Kirchhausen T. Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nat Chem Biol 2006, 2:39-46. 10.1038/nchembio751, 16408091.
72. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008, 68(21):8899-8907. 10.1158/0008-5472.CAN-08-2568, 2596920, 18974134.
73. Tischler J, Lehner B, Fraser AG. Evolutionary plasticity of genetic interaction networks. Nat Genet 2008, 40(4):390-391. 10.1038/ng.114, 18362882.
74. Tarailo M, Tarailo S, Rose AM. Synthetic lethal interactions identify phenotypic "interologs" of the spindle assembly checkpoint components. Genetics 2007, 177(4):2525-2530. 10.1534/genetics.107.080408, 2219473, 18073444.
75. Dixon SJ, Fedyshyn Y, Koh JLY, Prasad TSK, Chahwan C, Chua G, Toufighi K, Baryshnikova A, Hayles J, Hoe KL, Kim DU, Park HO, Myers CL, Pandey A, Durocher D, Andrews BJ, Boone C. Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. Proc Natl Acad Sci USA 2008, 105(43):16653-16658. 10.1073/pnas.0806261105, 2575475, 18931302.
76. Measday V, Baetz K, Guzzo J, Yuen K, Kwok T, Sheikh B, Ding H, Ueta R, Hoac T, Cheng B, Pot I, Tong A, Yamaguchi-Iwai Y, Boone C, Hieter P, Andrews B. Systematic yeast synthetic lethal and synthetic dosage lethal screens identify genes required for chromosome segregation. Proc Natl Acad Sci USA 2005, 102(39):13956-13961. 10.1073/pnas.0503504102, 1236538, 16172405.
77. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999, 9(12):M57-M60. 10.1016/S0962-8924(99)01661-X, 10611684.
78. Aggarwal M, Brosh RM. Hitting the bull's eye: novel directed cancer therapy through helicase-targeted synthetic lethality. J Cell Biochem 2009, 106(5):758-763. 10.1002/jcb.22048, 19173305.